Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15031600,"peak plasma 1,25-D(3) concentrations (Cp(max))","After 0.125 and 0.5 microg dosing, peak plasma 1,25-D(3) concentrations (Cp(max)) were 12.0 ng/ml (CI 95%, 10.8-12.6) and 41.6 ng/ml (CI 95%, 40.8-53.6), respectively.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[ng] / [ml],12.0,664,DB00169,Cholecalciferol
,15031600,"peak plasma 1,25-D(3) concentrations (Cp(max))","After 0.125 and 0.5 microg dosing, peak plasma 1,25-D(3) concentrations (Cp(max)) were 12.0 ng/ml (CI 95%, 10.8-12.6) and 41.6 ng/ml (CI 95%, 40.8-53.6), respectively.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[ng] / [ml],41.6,665,DB00169,Cholecalciferol
,15031600,areas under the curve (AUC(0->24 h)),"The corresponding areas under the curve (AUC(0->24 h)) were 47.0 (CI 95%, 43.2-51.1) and 128.0 (CI 95%, 127.0-130.0) ng.h/ml.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[h·ng] / [ml],47.0,666,DB00169,Cholecalciferol
,15031600,areas under the curve (AUC(0->24 h)),"The corresponding areas under the curve (AUC(0->24 h)) were 47.0 (CI 95%, 43.2-51.1) and 128.0 (CI 95%, 127.0-130.0) ng.h/ml.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[h·ng] / [ml],128.0,667,DB00169,Cholecalciferol
,17317832,C(max),Mean (+/-SD) serum calcitriol C(max) at the MTD was 6.68 +/- 1.42 ng/mL.,A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317832/),[ng] / [ml],6.68,5382,DB00169,Cholecalciferol
,3631255,metabolic clearance rate,"By use of this technique we found that the metabolic clearance rate of 1,25-dihydroxyvitamin D3 in dogs was 6.3 +/- 1.2 ml/min (mean +/- SD); the production rate of the hormone was 0.40 +/- 0.25 microgram/day (20.4 +/- 14.4 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ml] / [min],6.3,5713,DB00169,Cholecalciferol
,3631255,production rate,"By use of this technique we found that the metabolic clearance rate of 1,25-dihydroxyvitamin D3 in dogs was 6.3 +/- 1.2 ml/min (mean +/- SD); the production rate of the hormone was 0.40 +/- 0.25 microgram/day (20.4 +/- 14.4 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[μg] / [d],0.40,5714,DB00169,Cholecalciferol
,3631255,production rate,"By use of this technique we found that the metabolic clearance rate of 1,25-dihydroxyvitamin D3 in dogs was 6.3 +/- 1.2 ml/min (mean +/- SD); the production rate of the hormone was 0.40 +/- 0.25 microgram/day (20.4 +/- 14.4 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ng] / [d·kg],20.4,5715,DB00169,Cholecalciferol
,3631255,metabolic clearance rate,"In eight normal women, aged 28-51 yr, the metabolic clearance rate for 1,25-dihydroxyvitamin D3 was 25.9 +/- 4.7 ml/min; the production rate was 1.38 +/- 0.45 microgram/day (20.7 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ml] / [min],25.9,5716,DB00169,Cholecalciferol
,3631255,production rate,"In eight normal women, aged 28-51 yr, the metabolic clearance rate for 1,25-dihydroxyvitamin D3 was 25.9 +/- 4.7 ml/min; the production rate was 1.38 +/- 0.45 microgram/day (20.7 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[μg] / [d],1.38,5717,DB00169,Cholecalciferol
,3631255,production rate,"In eight normal women, aged 28-51 yr, the metabolic clearance rate for 1,25-dihydroxyvitamin D3 was 25.9 +/- 4.7 ml/min; the production rate was 1.38 +/- 0.45 microgram/day (20.7 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ng] / [d·kg],20.7,5718,DB00169,Cholecalciferol
,16411524,maximum serum concentration,"The maximum serum concentration after IP administration of 10 microg OCT was 750 pg/mL after 5 minutes, and remained at 500 pg/mL at 60 minutes.",Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411524/),[pg] / [ml],750,9093,DB00169,Cholecalciferol
,16411524,maximum serum concentration,"The maximum serum concentration after IP administration of 10 microg OCT was 750 pg/mL after 5 minutes, and remained at 500 pg/mL at 60 minutes.",Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411524/),[pg] / [ml],500,9094,DB00169,Cholecalciferol
,24854296,half-life,These results coupled with a pharmacokinetic half-life of ~24 h suggest that 2MD given either daily or at the time of dialysis may be a superior therapy for secondary hyperparathyroidism in chronic renal failure patients.,"Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854296/),h,24,12317,DB00169,Cholecalciferol
,26333524,ch,In vivo performance showed a greater mean change from baseline cholecalciferol to peak plasma levels (Cmax) from the BAP compared to the comparator (55.66 versus 46.05 ng/mL).,A novel bile salts-lipase polymeric film-infused minitablet system for enhanced oral delivery of cholecalciferol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333524/),[ng] / [ml],55.66,15916,DB00169,Cholecalciferol
,26333524,ch,In vivo performance showed a greater mean change from baseline cholecalciferol to peak plasma levels (Cmax) from the BAP compared to the comparator (55.66 versus 46.05 ng/mL).,A novel bile salts-lipase polymeric film-infused minitablet system for enhanced oral delivery of cholecalciferol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333524/),[ng] / [ml],46.05,15917,DB00169,Cholecalciferol
,26333524,to peak plasma levels (Cmax),In vivo performance showed a greater mean change from baseline cholecalciferol to peak plasma levels (Cmax) from the BAP compared to the comparator (55.66 versus 46.05 ng/mL).,A novel bile salts-lipase polymeric film-infused minitablet system for enhanced oral delivery of cholecalciferol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333524/),[ng] / [ml],55.66,15918,DB00169,Cholecalciferol
,26333524,to peak plasma levels (Cmax),In vivo performance showed a greater mean change from baseline cholecalciferol to peak plasma levels (Cmax) from the BAP compared to the comparator (55.66 versus 46.05 ng/mL).,A novel bile salts-lipase polymeric film-infused minitablet system for enhanced oral delivery of cholecalciferol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333524/),[ng] / [ml],46.05,15919,DB00169,Cholecalciferol
,28905271,half-life,"After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively).","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,55.8,28814,DB00169,Cholecalciferol
,28905271,half-life,"After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively).","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,50.8,28815,DB00169,Cholecalciferol
,28905271,time to maximum plasma concentration,"At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,4.0,28816,DB00169,Cholecalciferol
,28905271,concentration maximum,"At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[pg] / [ml],3.4,28817,DB00169,Cholecalciferol
,28905271,area under the curve (0 to infinity),"The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[h·pg] / [ml],204.3,28818,DB00169,Cholecalciferol
,28905271,apparent volume of distribution,"The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[l] / [kg],2.03,28819,DB00169,Cholecalciferol
,28445901,AUCinf,"For example: Cmax (ng/mL) and AUCinf (ng.h/mL) derived after the baseline corrections were 708.65 and 38 877.18 for reference and 743.71 and 40 665.51 for test, respectively.",Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445901/),[h·ng] / [ml],708.65,29173,DB00169,Cholecalciferol
,28445901,AUCinf,"For example: Cmax (ng/mL) and AUCinf (ng.h/mL) derived after the baseline corrections were 708.65 and 38 877.18 for reference and 743.71 and 40 665.51 for test, respectively.",Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445901/),[h·ng] / [ml],38 877.18,29174,DB00169,Cholecalciferol
,28445901,AUCinf,"For example: Cmax (ng/mL) and AUCinf (ng.h/mL) derived after the baseline corrections were 708.65 and 38 877.18 for reference and 743.71 and 40 665.51 for test, respectively.",Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445901/),[h·ng] / [ml],743.71,29175,DB00169,Cholecalciferol
,28445901,AUCinf,"For example: Cmax (ng/mL) and AUCinf (ng.h/mL) derived after the baseline corrections were 708.65 and 38 877.18 for reference and 743.71 and 40 665.51 for test, respectively.",Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28445901/),[h·ng] / [ml],40 665.51,29176,DB00169,Cholecalciferol
,8494933,peak levels,"Serum calcitriol levels reached peak levels of 60 and 70 pg/mL at 1 and 2 hours after administration, respectively.",The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494933/),[pg] / [ml],60,31616,DB00169,Cholecalciferol
,8494933,peak levels,"Serum calcitriol levels reached peak levels of 60 and 70 pg/mL at 1 and 2 hours after administration, respectively.",The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494933/),[pg] / [ml],70,31617,DB00169,Cholecalciferol
,8494933,area under the curve (AUC),The mean value of the area under the curve (AUC) was 809 +/- 226 pg/mL/hour.,The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494933/),[pg] / [h·ml],809,31618,DB00169,Cholecalciferol
,9219897,half-life,"The concentration of 24,25-(OH)2D3 in plasma reached a maximum after 6 h and decayed in two distinct phases; a fast-phase with a half-life of 17 h, followed by a slow-phase with a 17-day half-life.","In vivo metabolism of 24R,25-dihydroxyvitamin D3: structure of its major bile metabolite. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219897/),h,17,32416,DB00169,Cholecalciferol
,9219897,half-life,"The concentration of 24,25-(OH)2D3 in plasma reached a maximum after 6 h and decayed in two distinct phases; a fast-phase with a half-life of 17 h, followed by a slow-phase with a 17-day half-life.","In vivo metabolism of 24R,25-dihydroxyvitamin D3: structure of its major bile metabolite. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219897/),d,17,32417,DB00169,Cholecalciferol
,16759888,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) administered IVAG at 1.0microg/kg BW was approximately 93%.","Dose response to vaginal administration of 1,25-dihydroxyvitamin D3 to cows. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759888/),%,93,32669,DB00169,Cholecalciferol
,8704116,AUC0-0.5,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,105,33067,DB00169,Cholecalciferol
,8704116,AUC0-0.5,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,9,33068,DB00169,Cholecalciferol
,8704116,AUC0.5-1,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,68,33069,DB00169,Cholecalciferol
,8704116,AUC0.5-1,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,30,33070,DB00169,Cholecalciferol
,8704116,t1/2,Individual t1/2 values ranged from 10 to 129 h for PK1 and from 10 to 50 h for PK2.,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,10 to 129,33071,DB00169,Cholecalciferol
,8704116,t1/2,Individual t1/2 values ranged from 10 to 129 h for PK1 and from 10 to 50 h for PK2.,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,10 to 50,33072,DB00169,Cholecalciferol
,8704116,t1/2,The t1/2 for oral calcitriol was 38 +/- 14 h for PK1 and 30 +/- 4 h for PK2 (not significant (NS)).,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,38,33073,DB00169,Cholecalciferol
,8704116,t1/2,The t1/2 for oral calcitriol was 38 +/- 14 h for PK1 and 30 +/- 4 h for PK2 (not significant (NS)).,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,30,33074,DB00169,Cholecalciferol
,8704116,t1/2,"The t1/2 for i.v. calcitriol was 26 +/- 5 h for PK1 and 19 +/- 3 h for PK2 (NS, PK1 versus PK2 and oral versus i.v.).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,26,33075,DB00169,Cholecalciferol
,8704116,t1/2,"The t1/2 for i.v. calcitriol was 26 +/- 5 h for PK1 and 19 +/- 3 h for PK2 (NS, PK1 versus PK2 and oral versus i.v.).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,19,33076,DB00169,Cholecalciferol
,8704116,t1/2,"When the PK1 oral and i.v. data were combined, the mean t1/2 was 32 +/- 7 h whereas the t1/2 for PK2 (oral and i.v.) was 22 +/- 3 h (P < 0.05).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,32,33077,DB00169,Cholecalciferol
,8704116,t1/2,"When the PK1 oral and i.v. data were combined, the mean t1/2 was 32 +/- 7 h whereas the t1/2 for PK2 (oral and i.v.) was 22 +/- 3 h (P < 0.05).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,22,33078,DB00169,Cholecalciferol
,2996826,metabolic clearance rate,"The metabolic clearance rate of 1,25-dihydroxyvitamin D3 was the same in both normal heterozygous (0.90 +/- 0.02) and hypocalcaemic, homozygous piglets (0.90 +/- 0.01 ml-1 min-1 kg-1 metabolic body size).","Effect of 1,25-dihydroxyvitamin D deficiency on the metabolic clearance rate of 1,25-dihydroxyvitamin D3: studies using pigs with vitamin D-dependent rickets type 1. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2996826/),1/[kg·min·ml],0.90,33574,DB00169,Cholecalciferol
,2996826,metabolic clearance rate,"The metabolic clearance rate of 1,25-dihydroxyvitamin D3 was the same in both normal heterozygous (0.90 +/- 0.02) and hypocalcaemic, homozygous piglets (0.90 +/- 0.01 ml-1 min-1 kg-1 metabolic body size).","Effect of 1,25-dihydroxyvitamin D deficiency on the metabolic clearance rate of 1,25-dihydroxyvitamin D3: studies using pigs with vitamin D-dependent rickets type 1. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2996826/),1/[kg·min·ml],0.90,33575,DB00169,Cholecalciferol
,2058667,steady-state levels,Conscious adult (7-mo-old) and aged (25-mo-old) male Sprague-Dawley rats were infused for 2 h with rat PTH-(1-34) to achieve steady-state levels in plasma (110-120 pg/ml).,Heterogeneous response to PTH in aging rats: evidence for skeletal PTH resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058667/),[pg] / [ml],110-120,34018,DB00169,Cholecalciferol
,2058667,metabolic clearance rate,"The metabolic clearance rate of irPTH was rapid and not different in adult and aged rats (99 +/- 8 vs. 111 +/- 7 ml.min-1.kg-1, respectively).",Heterogeneous response to PTH in aging rats: evidence for skeletal PTH resistance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058667/),[ml] / [kg·min],99,34019,DB00169,Cholecalciferol
,2058667,metabolic clearance rate,"The metabolic clearance rate of irPTH was rapid and not different in adult and aged rats (99 +/- 8 vs. 111 +/- 7 ml.min-1.kg-1, respectively).",Heterogeneous response to PTH in aging rats: evidence for skeletal PTH resistance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058667/),[ml] / [kg·min],111,34020,DB00169,Cholecalciferol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.7,34760,DB00169,Cholecalciferol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.8,34761,DB00169,Cholecalciferol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.8,34762,DB00169,Cholecalciferol
,2709678,production,"25(OH)D treatment did not affect production rates in normal dogs and in animals with moderate renal failure (with normal basal values of 1,25(OH)2D), but significantly increased 1,25(OH)2D production from 0.13 +/- 0.01 to 0.25 +/- 0.04 micrograms/day (P less than 0.05) in dogs with severe renal insufficiency.",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),,0,34763,DB00169,Cholecalciferol
,21477267,T(max),The median for digoxin T(max) was 0.75 h before and after vitamin D3 ingestion.,Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin--a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477267/),h,0.75,41061,DB00169,Cholecalciferol
,31518424,rate to reach steady state,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,7,44141,DB00169,Cholecalciferol
,31518424,time to reach,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,7,44142,DB00169,Cholecalciferol
,31518424,time to reach,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,10,44143,DB00169,Cholecalciferol
,31518424,time to reach,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,40,44144,DB00169,Cholecalciferol
,20921291,area under the curve over 48 h (AUC(0-48)),"Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48 h (AUC(0-48)) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respectively; P = 0.171].",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],429,46285,DB00169,Cholecalciferol
,20921291,area under the curve over 48 h (AUC(0-48)),"Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48 h (AUC(0-48)) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respectively; P = 0.171].",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],318,46286,DB00169,Cholecalciferol
,20921291,AUC(0-48),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],137,46287,DB00169,Cholecalciferol
,20921291,AUC(0-48),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],318,46288,DB00169,Cholecalciferol
,20921291,C(max),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[pg] / [ml],40.1,46289,DB00169,Cholecalciferol
,20921291,C(max),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[pg] / [ml],49.7,46290,DB00169,Cholecalciferol
,7923966,Cmax,"The highest measured concentrations of 1,25(OH)2D3 were found at 1.5 h for both oral and IP treatments (mean Cmax [SD]: oral 116 [23] pmol/l, IP 121 [24] pmol/l, p > 0.05).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [l],116,47523,DB00169,Cholecalciferol
,7923966,Cmax,"The highest measured concentrations of 1,25(OH)2D3 were found at 1.5 h for both oral and IP treatments (mean Cmax [SD]: oral 116 [23] pmol/l, IP 121 [24] pmol/l, p > 0.05).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [l],121,47524,DB00169,Cholecalciferol
,7923966,AUC's,"The AUC's for oral and IP therapy were similar (1701 [276] and 1645 [301] pmol/h/l, respectively).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [h·l],1701,47525,DB00169,Cholecalciferol
,7923966,AUC's,"The AUC's for oral and IP therapy were similar (1701 [276] and 1645 [301] pmol/h/l, respectively).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [h·l],1645,47526,DB00169,Cholecalciferol
,7923966,serum half life,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,27.4,47527,DB00169,Cholecalciferol
,7923966,serum half life,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,19.2,47528,DB00169,Cholecalciferol
,7923966,total body clearance,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,15.3,47529,DB00169,Cholecalciferol
,7923966,total body clearance,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,18.4,47530,DB00169,Cholecalciferol
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[pg] / [ml],30.4,50094,DB00169,Cholecalciferol
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),nM,0.07,50095,DB00169,Cholecalciferol
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[pg] / [ml],104,50096,DB00169,Cholecalciferol
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),nM,0.25,50097,DB00169,Cholecalciferol
,14586212,AUCs,"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[h·pg] / [ml],222.5,50098,DB00169,Cholecalciferol
,14586212,AUCs,"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[h·pg] / [ml],855,50099,DB00169,Cholecalciferol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],25.8,51628,DB00169,Cholecalciferol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],20.2,51629,DB00169,Cholecalciferol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],20.2,51630,DB00169,Cholecalciferol
,2405696,apparent volume of distribution,"Similarly, the apparent volume of distribution of 1,25(OH)2D in the pregnant rats (15 +/- 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 +/- 2.1 ml).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),ml,15,51631,DB00169,Cholecalciferol
,2405696,apparent volume of distribution,"Similarly, the apparent volume of distribution of 1,25(OH)2D in the pregnant rats (15 +/- 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 +/- 2.1 ml).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),ml,18,51632,DB00169,Cholecalciferol
,2405696,Production rates,"Production rates of.1,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[pg] / [min],2.83,51633,DB00169,Cholecalciferol
,2405696,Production rates,"Production rates of.1,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[pg] / [min],1.55,51634,DB00169,Cholecalciferol
,20306264,MTD,"In an earlier canine study, the MTD of intravenous (i.v.) calcitriol was 3.75 μg/kg, but polysorbate-associated hypersensitivity reactions were common.","Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306264/),[μg] / [kg],3.75,52288,DB00169,Cholecalciferol
,20306264,oral bioavailability,"Calcitriol oral bioavailability was highly variable among dogs (mean ± SEM, 71 ± 12.6%).","Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306264/),%,71,52289,DB00169,Cholecalciferol
,8368291,metabolic clearance rate,"Diabetic rats had an increased metabolic clearance rate of 1,25-(OH)2D3 (0.38 +/- 0.015 vs. 0.24 +/- 0.007 ml.min-1.kg-1), with no further increase in 1,25(OH)2D3-infused diabetic rats; their relative production rate of 1,25(OH)2D3 was unchanged.","Increased clearance of 1,25(OH)2D3 and tissue-specific responsiveness to 1,25(OH)2D3 in diabetic rats. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368291/),[ml] / [kg·min],0.38,53280,DB00169,Cholecalciferol
,8368291,metabolic clearance rate,"Diabetic rats had an increased metabolic clearance rate of 1,25-(OH)2D3 (0.38 +/- 0.015 vs. 0.24 +/- 0.007 ml.min-1.kg-1), with no further increase in 1,25(OH)2D3-infused diabetic rats; their relative production rate of 1,25(OH)2D3 was unchanged.","Increased clearance of 1,25(OH)2D3 and tissue-specific responsiveness to 1,25(OH)2D3 in diabetic rats. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368291/),[ml] / [kg·min],0.24,53281,DB00169,Cholecalciferol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],96,54314,DB00169,Cholecalciferol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],105,54315,DB00169,Cholecalciferol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],161,54316,DB00169,Cholecalciferol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],222,54317,DB00169,Cholecalciferol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[h·μg] / [dl],188,54318,DB00169,Cholecalciferol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[h·μg] / [dl],302,54319,DB00169,Cholecalciferol
,3392356,AUC,"Following Rocaltrol, serum calcium level increased (8.9 +/- .12 to 9.8 +/- .4 mg/dl, p less than 0.05), parathyroid hormone levels decreased (20.4 +/- 8.9 to 13.6 +/- 7.2 ng/ml, p less than 0.05), but there was no significant change in fasting plasma zinc, 2 hour plasma zinc, or AUC (89 +/- 3 micrograms/dl, 149 micrograms/dl, and 176 +/- 18 micrograms hr/dl, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],149,54320,DB00169,Cholecalciferol
,3392356,AUC,"Following Rocaltrol, serum calcium level increased (8.9 +/- .12 to 9.8 +/- .4 mg/dl, p less than 0.05), parathyroid hormone levels decreased (20.4 +/- 8.9 to 13.6 +/- 7.2 ng/ml, p less than 0.05), but there was no significant change in fasting plasma zinc, 2 hour plasma zinc, or AUC (89 +/- 3 micrograms/dl, 149 micrograms/dl, and 176 +/- 18 micrograms hr/dl, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[h·μg] / [dl],176,54321,DB00169,Cholecalciferol
,12031392,area under the concentration versus time curve,The mean total calcitriol exposure (area under the concentration versus time curve) in the prostate was 297.6 (+/-159) pg/hr/mL (intact) and 272.7 (+/-123.6) pg/hr/mL (castrated).,"Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12031392/),[pg] / [h·ml],297.6,62885,DB00169,Cholecalciferol
,12031392,area under the concentration versus time curve,The mean total calcitriol exposure (area under the concentration versus time curve) in the prostate was 297.6 (+/-159) pg/hr/mL (intact) and 272.7 (+/-123.6) pg/hr/mL (castrated).,"Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12031392/),[pg] / [h·ml],272.7,62886,DB00169,Cholecalciferol
,21632810,D₂,"From a common baseline D₂ (1.5 ± 1.6 nmol/liter, P =0.34) the groups diverged (time × group interaction P = 0.04), peaking at 70 ± 34 nmol/liter at 6 h in controls compared with 43 ± 28 nmol/liter in AN subjects (P = 0.008).",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],1.5,64360,DB00169,Cholecalciferol
,21632810,D₂,"From a common baseline D₂ (1.5 ± 1.6 nmol/liter, P =0.34) the groups diverged (time × group interaction P = 0.04), peaking at 70 ± 34 nmol/liter at 6 h in controls compared with 43 ± 28 nmol/liter in AN subjects (P = 0.008).",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],70,64361,DB00169,Cholecalciferol
,21632810,D₂,"From a common baseline D₂ (1.5 ± 1.6 nmol/liter, P =0.34) the groups diverged (time × group interaction P = 0.04), peaking at 70 ± 34 nmol/liter at 6 h in controls compared with 43 ± 28 nmol/liter in AN subjects (P = 0.008).",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],43,64362,DB00169,Cholecalciferol
,21632810,D₃,"Baseline D₃ was higher in AN subjects (12.1 ± 9.6 vs. 3.1 ± 2.3 nmol/liter, P < 0.001) and remained higher throughout.",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],12.1,64363,DB00169,Cholecalciferol
,21632810,D₃,"Baseline D₃ was higher in AN subjects (12.1 ± 9.6 vs. 3.1 ± 2.3 nmol/liter, P < 0.001) and remained higher throughout.",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],3.1,64364,DB00169,Cholecalciferol
,6897931,renal synthesis,Estimated renal synthesis ranged from 2-180 pmol/kg . day.,"Synthesis and metabolic clearance of 1,25-dihydroxyvitamin D as determinants of serum concentrations: a comparison of two methods. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897931/),[pM] / [d·kg],2-180,66244,DB00169,Cholecalciferol
<,21667092,Ca/Cr clearance ratio,"In the group of patients with Ca/Cr clearance ratio <0.01, seven patients had hypercalcemia, and four patients had hypercalcemia and elevated iPTH.",Impaired regulation of calcium excretion in kidney transplant recipients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21667092/),,0.01,66451,DB00169,Cholecalciferol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,13.9,68088,DB00169,Cholecalciferol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.1,68089,DB00169,Cholecalciferol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,12.8,68090,DB00169,Cholecalciferol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,14.7,68091,DB00169,Cholecalciferol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.1,68092,DB00169,Cholecalciferol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.6,68093,DB00169,Cholecalciferol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.03,68094,DB00169,Cholecalciferol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.04,68095,DB00169,Cholecalciferol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.04,68096,DB00169,Cholecalciferol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.06,68097,DB00169,Cholecalciferol
,18326608,concentration maximum,Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 27.1 +/- 7.7 ng/mL to a concentration maximum of 42.0 +/- 9.1 ng/mL.,"Pharmacokinetics of a single, large dose of cholecalciferol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18326608/),[ng] / [ml],42.0,69056,DB00169,Cholecalciferol
,18326608,highest achieved concentration,The highest achieved concentration in any subject was 64.2 ng/mL.,"Pharmacokinetics of a single, large dose of cholecalciferol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18326608/),[ng] / [ml],64.2,69057,DB00169,Cholecalciferol
,11413535,peak calcitriol levels,"Doses of 0.48 microg/kg and above produced mean peak calcitriol levels of 1625 pg/mL, approximately 25-fold greater than top normal levels and well within the therapeutic range suggested by in vitro experiments.",A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413535/),[pg] / [ml],1625,73473,DB00169,Cholecalciferol
,32691454,zeta-potential,The magnitude of negative zeta-potential increased from 3.1 to 31.0 mV at pH 2.0 to 7.4.,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),mv,3.1,74521,DB00169,Cholecalciferol
,32691454,zeta-potential,The magnitude of negative zeta-potential increased from 3.1 to 31.0 mV at pH 2.0 to 7.4.,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),mv,31.0,74522,DB00169,Cholecalciferol
,32691454,Bioaccessibility,Bioaccessibility of VD3 in capsules (95.76%) was significantly higher than the nonencapsulated VD3 (68.98%).,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),%,95.76,74523,DB00169,Cholecalciferol
,32691454,Bioaccessibility,Bioaccessibility of VD3 in capsules (95.76%) was significantly higher than the nonencapsulated VD3 (68.98%).,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),%,68.98,74524,DB00169,Cholecalciferol
,3667442,half-life,Physiological half-life of the tritiated 2500 HD3 in wethers exposed to ultraviolet irradiation was 388 +/- 26.4 h (means +/- SE); in the control it was 393 +/- 29.6 h (P greater than .05).,Kinetics of intravenously administered 25-hydroxyvitamin D3 in sheep and the effect of exposure to ultraviolet radiation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667442/),h,388,78066,DB00169,Cholecalciferol
,3667442,half-life,Physiological half-life of the tritiated 2500 HD3 in wethers exposed to ultraviolet irradiation was 388 +/- 26.4 h (means +/- SE); in the control it was 393 +/- 29.6 h (P greater than .05).,Kinetics of intravenously administered 25-hydroxyvitamin D3 in sheep and the effect of exposure to ultraviolet radiation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667442/),h,393,78067,DB00169,Cholecalciferol
,3428866,elimination half life,"Dietary calcium deficiency resulted in a small increase of the 1,25(OH)2D3 elimination half life (P = 0.04) (normal diet: 16.3 +/- 1.8 hrs, n = 6; -Ca diet: 18.6 +/- 1.1 hrs, n = 5; -P diet: 16.0 +/- 1.4 hrs, n = 6; mean +/- SD).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,16.3,89128,DB00169,Cholecalciferol
,3428866,elimination half life,"Dietary calcium deficiency resulted in a small increase of the 1,25(OH)2D3 elimination half life (P = 0.04) (normal diet: 16.3 +/- 1.8 hrs, n = 6; -Ca diet: 18.6 +/- 1.1 hrs, n = 5; -P diet: 16.0 +/- 1.4 hrs, n = 6; mean +/- SD).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,18.6,89129,DB00169,Cholecalciferol
,3428866,elimination half life,"Dietary calcium deficiency resulted in a small increase of the 1,25(OH)2D3 elimination half life (P = 0.04) (normal diet: 16.3 +/- 1.8 hrs, n = 6; -Ca diet: 18.6 +/- 1.1 hrs, n = 5; -P diet: 16.0 +/- 1.4 hrs, n = 6; mean +/- SD).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,16.0,89130,DB00169,Cholecalciferol
,3428866,elimination half life,"The experiments with the vitamin D deficient rats showed a marked increase in the elimination half life of 1,25(OH)2D3 (36.4 +/- 6.8 hrs, n = 7), when compared to the rats on the normal diet (P = 0.001).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,36.4,89131,DB00169,Cholecalciferol
,33115916,clearances,"Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).",Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115916/),[ml] / [d],360,90196,DB00169,Cholecalciferol
,33115916,clearances,"Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).",Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115916/),[ml] / [d],313,90197,DB00169,Cholecalciferol
,33115916,clearances,"Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).",Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115916/),[ml] / [d],263,90198,DB00169,Cholecalciferol
,18689406,half-life,The lipophilic nature of vitamin D explains its adipose tissue distribution and its slow turnover in the body (half-life approximately 2 mo).,Pharmacokinetics of vitamin D toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18689406/),mo,2,93723,DB00169,Cholecalciferol
,18689406,half-life,"Its main transported metabolite, 25-hydroxyvitamin D(3) [25(OH)D(3)], shows a half-life of approximately 15 d and circulates at a concentration of 25-200 nmol/L, whereas the hormone 1alpha,25(OH)(2)D(3) has a half-life of approximately 15 h.",Pharmacokinetics of vitamin D toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18689406/),d,15,93724,DB00169,Cholecalciferol
,18689406,half-life,"Its main transported metabolite, 25-hydroxyvitamin D(3) [25(OH)D(3)], shows a half-life of approximately 15 d and circulates at a concentration of 25-200 nmol/L, whereas the hormone 1alpha,25(OH)(2)D(3) has a half-life of approximately 15 h.",Pharmacokinetics of vitamin D toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18689406/),h,15,93725,DB00169,Cholecalciferol
,21342321,PTH,The patients who achieved target PTH of 16-32 pmol/L were 82% in the calcitriol and 67% in the alfacalcidol group (P = 0.44).,Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342321/),[pM] / [l],16-32,94563,DB00169,Cholecalciferol
,3838330,Urinary calcium excretion (UCa),Urinary calcium excretion (UCa) was significantly increased from 199 +/- 19 mg/24 hr during the control period to similar levels of 302 +/- 26 mg/24 hr after 0.25 microgram twice a day and 284 +/- 31 mg/24 hr after 0.50 microgram daily.,Pharmacokinetics and biologic effects of calcitriol in normal humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],199,95280,DB00169,Cholecalciferol
,3838330,Urinary calcium excretion (UCa),Urinary calcium excretion (UCa) was significantly increased from 199 +/- 19 mg/24 hr during the control period to similar levels of 302 +/- 26 mg/24 hr after 0.25 microgram twice a day and 284 +/- 31 mg/24 hr after 0.50 microgram daily.,Pharmacokinetics and biologic effects of calcitriol in normal humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],302,95281,DB00169,Cholecalciferol
,3838330,Urinary calcium excretion (UCa),Urinary calcium excretion (UCa) was significantly increased from 199 +/- 19 mg/24 hr during the control period to similar levels of 302 +/- 26 mg/24 hr after 0.25 microgram twice a day and 284 +/- 31 mg/24 hr after 0.50 microgram daily.,Pharmacokinetics and biologic effects of calcitriol in normal humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],284,95282,DB00169,Cholecalciferol
,3838330,UCa,"With 0.50 microgram twice a day, UCa was 417 +/- 36 mg/24 hr, a value greater than after the lower doses (p less than 0.05).",Pharmacokinetics and biologic effects of calcitriol in normal humans. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],417,95283,DB00169,Cholecalciferol
,28629804,Encapsulation Efficiency (EE),"The optimized formulation was found to have a mean particle size of 28.62±0.26μm, Encapsulation Efficiency (EE) of 94.4±5.4% and drug loading of 5.19±0.29% with CL:TS ratio of 2:1.",Zero order controlled release delivery of cholecalciferol from injectable biodegradable microsphere: In-vitro characterization and in-vivo pharmacokinetic studies. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629804/),%,94.4,95793,DB00169,Cholecalciferol
,28629804,CL:TS ratio,"The optimized formulation was found to have a mean particle size of 28.62±0.26μm, Encapsulation Efficiency (EE) of 94.4±5.4% and drug loading of 5.19±0.29% with CL:TS ratio of 2:1.",Zero order controlled release delivery of cholecalciferol from injectable biodegradable microsphere: In-vitro characterization and in-vivo pharmacokinetic studies. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629804/),,2:1,95794,DB00169,Cholecalciferol
,28629804,t1/2,In-vivo pharmacokinetic study of CL-MS showed higher t1/2 (239±27.5h) compared to oily CL depot (32.7±4.8h) with sustained release of CL plasma concentration for 1month.,Zero order controlled release delivery of cholecalciferol from injectable biodegradable microsphere: In-vitro characterization and in-vivo pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629804/),h,239,95795,DB00169,Cholecalciferol
,28629804,t1/2,In-vivo pharmacokinetic study of CL-MS showed higher t1/2 (239±27.5h) compared to oily CL depot (32.7±4.8h) with sustained release of CL plasma concentration for 1month.,Zero order controlled release delivery of cholecalciferol from injectable biodegradable microsphere: In-vitro characterization and in-vivo pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629804/),h,32.7,95796,DB00169,Cholecalciferol
,11037113,serum T(1/2),"4. In the male rat, the serum T(1/2) was 3 h, but in the female rat and minipig (both genders) T(1/2) = 8 h.",Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037113/),h,3,98053,DB00169,Cholecalciferol
,11037113,T(1/2),"4. In the male rat, the serum T(1/2) was 3 h, but in the female rat and minipig (both genders) T(1/2) = 8 h.",Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037113/),h,8,98054,DB00169,Cholecalciferol
,8399781,terminal serum half-time (t 1/2),"In the healthy subjects without calcium supplementation, the basal (24R)-hydroxycalcidiol concentration (Cb) in serum was 2.4 +/- 0.8 nmol/l (mean +/- SD, n = 5), the terminal serum half-time (t 1/2) 7.2 +/- 1.4 days, the production rate 0.05 +/- 0.01 nmol/kg.day, and the production rate/[calcidiol] ratio (1.5 +/- 0.4 x 10(-3) l/kg.day).",Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399781/),d,7.2,101529,DB00169,Cholecalciferol
,8399781,production rate,"In the healthy subjects without calcium supplementation, the basal (24R)-hydroxycalcidiol concentration (Cb) in serum was 2.4 +/- 0.8 nmol/l (mean +/- SD, n = 5), the terminal serum half-time (t 1/2) 7.2 +/- 1.4 days, the production rate 0.05 +/- 0.01 nmol/kg.day, and the production rate/[calcidiol] ratio (1.5 +/- 0.4 x 10(-3) l/kg.day).",Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399781/),[nM] / [d·kg],0.05,101530,DB00169,Cholecalciferol
,8399781,production rate/[calcidiol] ratio,"In the healthy subjects without calcium supplementation, the basal (24R)-hydroxycalcidiol concentration (Cb) in serum was 2.4 +/- 0.8 nmol/l (mean +/- SD, n = 5), the terminal serum half-time (t 1/2) 7.2 +/- 1.4 days, the production rate 0.05 +/- 0.01 nmol/kg.day, and the production rate/[calcidiol] ratio (1.5 +/- 0.4 x 10(-3) l/kg.day).",Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399781/),[l] / [d·kg],1.5,101531,DB00169,Cholecalciferol
,8263137,t1/2,"Clearance of the peptide from the circulation followed an expontential pattern, with a mean t1/2 of 75 min.",Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263137/),min,75,101757,DB00169,Cholecalciferol
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),[nM] / [ml],2499.4,104358,DB00169,Cholecalciferol
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),,7.8,104359,DB00169,Cholecalciferol
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),[nM] / [ml],2152.3,104360,DB00169,Cholecalciferol
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),,7.6,104361,DB00169,Cholecalciferol
,30917531,Tmax,Fourteen days were needed to reach Tmax by more than half the subjects in Group 1 compared to 45 days in Group 2.,"Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),,45,104362,DB00169,Cholecalciferol
,23681426,peak (Umax),"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109602,DB00169,Cholecalciferol
,23681426,Uave,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109603,DB00169,Cholecalciferol
,23681426,urinary excretion rate,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109604,DB00169,Cholecalciferol
,23681426,urinary excretion rate,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],0.901,109605,DB00169,Cholecalciferol
,23681426,time to reach Umax (Tmax),"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),h,6.77,109606,DB00169,Cholecalciferol
,23681426,total cumulative urinary excretion,"The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),μg,21.6,109607,DB00169,Cholecalciferol
,23681426,total cumulative urinary excretion,"The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),%,0.432,109608,DB00169,Cholecalciferol
,12506180,time to progression,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,11.4,111718,DB00169,Cholecalciferol
,12506180,survival,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,19.5,111719,DB00169,Cholecalciferol
,2997175,half-life,"24,25-Dihydroxyvitamin D3 disappeared from plasma with a half-life of 0.55 h (fast phase) and 73.8 h (slow phase).","Metabolism and pharmacokinetics of 24,25-dihydroxyvitamin D3 in the vitamin D3-replete rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2997175/),h,0.55,120386,DB00169,Cholecalciferol
,2997175,half-life,"24,25-Dihydroxyvitamin D3 disappeared from plasma with a half-life of 0.55 h (fast phase) and 73.8 h (slow phase).","Metabolism and pharmacokinetics of 24,25-dihydroxyvitamin D3 in the vitamin D3-replete rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2997175/),h,73.8,120387,DB00169,Cholecalciferol
,19427587,AUC(0-infinity),"In subjects, AUC(0-infinity) and AUC(0-24h) were 267 and 246 pg h ml(-1), respectively.",Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[h·pg] / [ml],267,125239,DB00169,Cholecalciferol
,19427587,AUC(0-24h),"In subjects, AUC(0-infinity) and AUC(0-24h) were 267 and 246 pg h ml(-1), respectively.",Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[h·pg] / [ml],246,125240,DB00169,Cholecalciferol
,19427587,C(max),The C(max) of calcitriol was measured at 3.4h after administration as 50.0 pg ml(-1).,Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[pg] / [ml],50.0,125241,DB00169,Cholecalciferol
,3184598,Plasma concentration,"Plasma concentration of calcitonin was significantly higher in 16-week-old SHR (41.6 +/- 1.5 pg/ml) than in age-matched WKY (30.5 +/- 1.7, P less than 0.001).",Calcitriol synthesis is decreased in spontaneously hypertensive rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184598/),[pg] / [ml],41.6,126675,DB00169,Cholecalciferol
,3184598,Plasma concentration,"Plasma concentration of calcitonin was significantly higher in 16-week-old SHR (41.6 +/- 1.5 pg/ml) than in age-matched WKY (30.5 +/- 1.7, P less than 0.001).",Calcitriol synthesis is decreased in spontaneously hypertensive rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184598/),,30.5,126676,DB00169,Cholecalciferol
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,19.0,129028,DB00169,Cholecalciferol
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,16.9,129029,DB00169,Cholecalciferol
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,20,132032,DB00169,Cholecalciferol
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,35.2,132033,DB00169,Cholecalciferol
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,51.3,132034,DB00169,Cholecalciferol
,2161692,alpha (peak fractional absorption/h),"Gastrointestinal absorption of 45Ca, as represented by alpha (peak fractional absorption/h), increased from 0.397 +/- 0.173 to 0.552 +/- 0.210 (P less than 0.01) during hPTH 1-38 therapy and was moderately correlated with the increment in serum 1,25(OH)2D levels (r = 0.5, P less than 0.03).",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,0.397,132374,DB00169,Cholecalciferol
,2161692,alpha (peak fractional absorption/h),"Gastrointestinal absorption of 45Ca, as represented by alpha (peak fractional absorption/h), increased from 0.397 +/- 0.173 to 0.552 +/- 0.210 (P less than 0.01) during hPTH 1-38 therapy and was moderately correlated with the increment in serum 1,25(OH)2D levels (r = 0.5, P less than 0.03).",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,0.552,132375,DB00169,Cholecalciferol
,2161692,u,"Baseline fasting urinary excretion of OH-proline increased during hPTH 1-38 treatment from 30.5 +/- 13.9 mol/mmol creatinine to 43.4 +/- 17.5 immediately after hPTH 1-38 infusion (P less than 0.025), and mean excretion was persistently higher than baseline during intermittent treatment; the increased urine calcium and OH-proline excretion are consistent with PTH-induced activation of bone resorption.",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,30.5,132376,DB00169,Cholecalciferol
,2161692,u,"Baseline fasting urinary excretion of OH-proline increased during hPTH 1-38 treatment from 30.5 +/- 13.9 mol/mmol creatinine to 43.4 +/- 17.5 immediately after hPTH 1-38 infusion (P less than 0.025), and mean excretion was persistently higher than baseline during intermittent treatment; the increased urine calcium and OH-proline excretion are consistent with PTH-induced activation of bone resorption.",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,43.4,132377,DB00169,Cholecalciferol
,23373428,limit of quantification (LOQ),The limit of quantification (LOQ) was 20 ng/mL for vitamin D3 and 40 ng/mL for K1.,A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ng] / [ml],20,136850,DB00169,Cholecalciferol
,23373428,limit of quantification (LOQ),The limit of quantification (LOQ) was 20 ng/mL for vitamin D3 and 40 ng/mL for K1.,A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ng] / [ml],40,136851,DB00169,Cholecalciferol
,23373428,AUC0-∞,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[h·ng] / [ml],11323,136852,DB00169,Cholecalciferol
,23373428,Vd,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [kg],218,136853,DB00169,Cholecalciferol
,23373428,CL,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [h·kg],8.9,136854,DB00169,Cholecalciferol
,23373428,t1/2,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),h,16.8,136855,DB00169,Cholecalciferol
,23373428,AUC0-∞,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[h·ng] / [ml],2495,136856,DB00169,Cholecalciferol
,23373428,Vd,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [kg],60,136857,DB00169,Cholecalciferol
,23373428,CL,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [h·kg],40.5,136858,DB00169,Cholecalciferol
,23373428,t1/2,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),h,1.1,136859,DB00169,Cholecalciferol
,18246349,MTD,"The MTD was 3.75 microg/kg calcitriol in combination with cisplatin, and hypercalcemia was the dose-limiting toxicosis.",In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18246349/),[μg] / [kg],3.75,137018,DB00169,Cholecalciferol
>,18246349,Cmax,Calcitriol dosages >1.5 microg/kg achieved Cmax > or = 9.8 ng/mL and dosages >1.0 microg/kg achieved AUC > or = 45 h ng/mL.,In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18246349/),[ng] / [ml],9.8,137019,DB00169,Cholecalciferol
>,18246349,AUC,Calcitriol dosages >1.5 microg/kg achieved Cmax > or = 9.8 ng/mL and dosages >1.0 microg/kg achieved AUC > or = 45 h ng/mL.,In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18246349/),[h·ng] / [ml],45,137020,DB00169,Cholecalciferol
,7999841,maximal,The median maximal decrease was 51.4% of baseline (22.3%-74%).,"Single-dose oral calcitriol and changes of plasma 1,84iPTH in uremic children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999841/),,51,141139,DB00169,Cholecalciferol
,2807147,half-lives,"The concentration-time curve of 24,25(OH)2D3 could be described by a two-exponential curve with half-lives of 3.0 +/- 0.9 hrs and 8.2 +/- 2.9 days (mean +/- SD).","Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2807147/),h,3.0,141504,DB00169,Cholecalciferol
,2807147,half-lives,"The concentration-time curve of 24,25(OH)2D3 could be described by a two-exponential curve with half-lives of 3.0 +/- 0.9 hrs and 8.2 +/- 2.9 days (mean +/- SD).","Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2807147/),d,8.2,141505,DB00169,Cholecalciferol
,2807147,volume of distribution,The volume of distribution was 0.19 +/- 0.02 liters/kg.,"Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2807147/),[l] / [kg],0.19,141506,DB00169,Cholecalciferol
,2807147,plateau level,"In 18 subjects suffering from primary hyperparathyroidism, taking 25 micrograms of 24,25(OH)2D3 daily during three months, an average plateau level of 39 +/- 12 nmol/l of serum was observed.","Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2807147/),[nM] / [l],39,141507,DB00169,Cholecalciferol
,2807147,Bioavailability,Bioavailability as estimated from this plateau level was approximately 70%.,"Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2807147/),%,70,141508,DB00169,Cholecalciferol
,10705507,specific radioactivity,"[22,23-(3)H4]1 alpha OHD3 (5) showed high specific radioactivity (111.5 Ci/mmol) and was used successfully in pharmacokinetics studies with rats.",Synthesis and pharmacokinetics of 1 alpha-hydroxyvitamin D3 tritiated at 22 and 23 positions showing high specific radioactivity. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10705507/),[ci] / [mM],111.5,141974,DB00169,Cholecalciferol
,23435876,RP2D,"The RP2D of 1,25-D3 was 60 mcg/m(2).",A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435876/),[mcg] / [m(2],60,143231,DB00169,Cholecalciferol
,23435876,time to progression,"Median time to progression was 5.8 months (95 % CI 3.4, 6.5), and median overall survival 8.7 months (95 % CI 7.6, 39.4).",A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435876/),month,5.8,143232,DB00169,Cholecalciferol
,23435876,overall survival,"Median time to progression was 5.8 months (95 % CI 3.4, 6.5), and median overall survival 8.7 months (95 % CI 7.6, 39.4).",A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435876/),month,8.7,143233,DB00169,Cholecalciferol
,22936122,formation rate constant (k(f)),"The mean population parameter estimates and the associated between-subject variability were: formation rate constant (k(f)), 0.11 day(-1); clearance (CL/F), 2.5 L/day (0.42); central volume of distribution (V(C)/F), 237 L; basal concentration (C(0)),12.82 ng/mL (0.41).",Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936122/),1/[day],0.11,147193,DB00169,Cholecalciferol
,22936122,clearance (CL/F),"The mean population parameter estimates and the associated between-subject variability were: formation rate constant (k(f)), 0.11 day(-1); clearance (CL/F), 2.5 L/day (0.42); central volume of distribution (V(C)/F), 237 L; basal concentration (C(0)),12.82 ng/mL (0.41).",Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936122/),[l] / [d],2.5,147194,DB00169,Cholecalciferol
,22936122,central volume of distribution (V(C)/F),"The mean population parameter estimates and the associated between-subject variability were: formation rate constant (k(f)), 0.11 day(-1); clearance (CL/F), 2.5 L/day (0.42); central volume of distribution (V(C)/F), 237 L; basal concentration (C(0)),12.82 ng/mL (0.41).",Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936122/),l,237,147195,DB00169,Cholecalciferol
,22936122,basal concentration (C(0)),"The mean population parameter estimates and the associated between-subject variability were: formation rate constant (k(f)), 0.11 day(-1); clearance (CL/F), 2.5 L/day (0.42); central volume of distribution (V(C)/F), 237 L; basal concentration (C(0)),12.82 ng/mL (0.41).",Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936122/),[ng] / [ml],12.82,147196,DB00169,Cholecalciferol
,3006671,half-lives,Pharmacokinetic analysis of the changes in D3 concentration in rats showed that the disposition kinetics of D3 was explained by a two-compartment model with half-lives of 13.8 and 7.7 days.,Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),d,13.8,152948,DB00169,Cholecalciferol
,3006671,half-lives,Pharmacokinetic analysis of the changes in D3 concentration in rats showed that the disposition kinetics of D3 was explained by a two-compartment model with half-lives of 13.8 and 7.7 days.,Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),d,7.7,152949,DB00169,Cholecalciferol
,3006671,volume of distribution,"The volume of distribution of the more-slowly-turning-over compartment was 500 ml, which presumably reflects the large amounts of D3 that can accumulate in adipose tissue.",Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),ml,500,152950,DB00169,Cholecalciferol
,3006671,t1/2,"Adipose-tissue D3 is available for use by the rat, the t1/2 being 12.0 days.",Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),d,12.0,152951,DB00169,Cholecalciferol
,10972662,AUC0-72h,"The peak serum level of 1,25(OH)2D3 and area under the curve baseline to 72 hours (AUC0-72h) were significantly higher after intravenous (IV) calcitriol (AUC0-72h oral, 1399 +/- 979 pg/mL. hour vs. IV 2793 +/- 1102 pg/mL. hour, P < 0.01), but the mean intestinal Sr absorption was not different [SrAUC0-240min during the 4 hours after Sr administration 2867 +/- 1101 FAD% (fraction of the absorbed dose) vs. 3117 +/- 1581 FAD% with oral and IV calcitriol, respectively].",No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972662/),[pg] / [h·ml],1399,154112,DB00169,Cholecalciferol
,10972662,AUC0-72h,"The peak serum level of 1,25(OH)2D3 and area under the curve baseline to 72 hours (AUC0-72h) were significantly higher after intravenous (IV) calcitriol (AUC0-72h oral, 1399 +/- 979 pg/mL. hour vs. IV 2793 +/- 1102 pg/mL. hour, P < 0.01), but the mean intestinal Sr absorption was not different [SrAUC0-240min during the 4 hours after Sr administration 2867 +/- 1101 FAD% (fraction of the absorbed dose) vs. 3117 +/- 1581 FAD% with oral and IV calcitriol, respectively].",No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972662/),[pg] / [h·ml],2793,154113,DB00169,Cholecalciferol
,11981071,bioavailability,"After oral administration of 1,25(OH)(2)D(3) the bioavailability of 1,25(OH)(2)D(3) was 70.6+/-5.8/72.2+/-4.8% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,70.6,154805,DB00169,Cholecalciferol
,11981071,bioavailability,"After oral administration of 1,25(OH)(2)D(3) the bioavailability of 1,25(OH)(2)D(3) was 70.6+/-5.8/72.2+/-4.8% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,72.2,154806,DB00169,Cholecalciferol
,11981071,volume of distribution,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[l] / [kg],0.49,154807,DB00169,Cholecalciferol
,11981071,volume of distribution,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[l] / [kg],0.27,154808,DB00169,Cholecalciferol
,11981071,metabolic clearance rate,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[ml] / [min],23.5,154809,DB00169,Cholecalciferol
,11981071,metabolic clearance rate,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[ml] / [min],10.1,154810,DB00169,Cholecalciferol
,11981071,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) after i.v. administration of 1alpha(OH)D(3) was 42.4+/-11.0/42.0+/-2.0% in healthy volunteers/uraemic patients (n.s.); and after oral administration of 1alpha(OH)D(3) 42.0+/-2.0/29.8+/-3.1% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,42.4,154811,DB00169,Cholecalciferol
,11981071,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) after i.v. administration of 1alpha(OH)D(3) was 42.4+/-11.0/42.0+/-2.0% in healthy volunteers/uraemic patients (n.s.); and after oral administration of 1alpha(OH)D(3) 42.0+/-2.0/29.8+/-3.1% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,42.0,154812,DB00169,Cholecalciferol
,11981071,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) after i.v. administration of 1alpha(OH)D(3) was 42.4+/-11.0/42.0+/-2.0% in healthy volunteers/uraemic patients (n.s.); and after oral administration of 1alpha(OH)D(3) 42.0+/-2.0/29.8+/-3.1% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,29.8,154813,DB00169,Cholecalciferol
,23484100,Tmax,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,2,156369,DB00169,Cholecalciferol
,23484100,Cmax,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),μM,0.7,156370,DB00169,Cholecalciferol
,23484100,T1/2,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,18,156371,DB00169,Cholecalciferol
,23484100,T1/2,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,21,156372,DB00169,Cholecalciferol
,23484100,AUC,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),[h·ng] / [ml],9221,156373,DB00169,Cholecalciferol
,23484100,AUC,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),[h·ng] / [ml],9818,156374,DB00169,Cholecalciferol
,23484100,Tmax,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,6,156375,DB00169,Cholecalciferol
,23484100,Cmax,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),M·μ,0.57,156376,DB00169,Cholecalciferol
,23484100,T1/2,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,8.3,156377,DB00169,Cholecalciferol
,23484100,AUC,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),[h·ng] / [ml],6474,156378,DB00169,Cholecalciferol
,33099115,flow rate,"Chromatographic separation was carried out on Kinetex C18 column (1.7 μm, 100 × 2.10 mm) under an isocratic elution at a flow rate of 0.4 mL/min with a total runtime of 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),[ml] / [min],0.4,158233,DB00169,Cholecalciferol
,33099115,total runtime,"Chromatographic separation was carried out on Kinetex C18 column (1.7 μm, 100 × 2.10 mm) under an isocratic elution at a flow rate of 0.4 mL/min with a total runtime of 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),min,3.5,158234,DB00169,Cholecalciferol
,33099115,total run time,"Additionally, only 20 μL of rat whole blood or plasma is required and the total run time per sample is 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),min,3.5,158235,DB00169,Cholecalciferol
,2382648,bioavailability,"The bioavailability of calcitriol, determined from the 24-hour area under the curve (AUC0-24) for the increase in serum calcitriol concentration above baseline values was 50% to 60% greater after IV, 2,340 +/- 523 pg.",Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382648/),%,50,159780,DB00169,Cholecalciferol
,2382648,bioavailability,"The bioavailability of calcitriol, determined from the 24-hour area under the curve (AUC0-24) for the increase in serum calcitriol concentration above baseline values was 50% to 60% greater after IV, 2,340 +/- 523 pg.",Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382648/),%,60,159781,DB00169,Cholecalciferol
,2382648,bioavailability,"The bioavailability of calcitriol, determined from the 24-hour area under the curve (AUC0-24) for the increase in serum calcitriol concentration above baseline values was 50% to 60% greater after IV, 2,340 +/- 523 pg.",Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382648/),pg,"2,340",159782,DB00169,Cholecalciferol
,30562554,terminal half-life,The terminal half-life of calcipotriol was approximately 1 h after an IV dose.,Pharmacokinetics of intra-articular vitamin D analogue calcipotriol in sheep and metabolism in human synovial and mesenchymal stromal cells. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562554/),h,1,159880,DB00169,Cholecalciferol
,30562554,systemic absorption,"After intra-articular dosing, the systemic absorption was between 1 and 13% during the observed 24 h.",Pharmacokinetics of intra-articular vitamin D analogue calcipotriol in sheep and metabolism in human synovial and mesenchymal stromal cells. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562554/),%,1 and 13,159881,DB00169,Cholecalciferol
,6982388,t1/2,"When oral treatment was stopped, or following the intravenous administration of 24,25(OH)2D3, plasma disappearance of 24,25(OH)2D3 was slow (t1/2 approx. 16 days).","Effects of 24,25-dihydroxy-vitamin D3 on its plasma level in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6982388/),d,16,160350,DB00169,Cholecalciferol
,15956292,bioavaila,"A second study was conducted to determine whether the bioavailability of vitamin D2 in cheese (delivering 5880 IU of vitamin D2/56.7-g serving) and water (delivering 32,750 IU/250 mL) is similar and whether absorption differs between younger and older adults.",Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956292/),,58,160553,DB00169,Cholecalciferol
,15956292,bioavaila,"A second study was conducted to determine whether the bioavailability of vitamin D2 in cheese (delivering 5880 IU of vitamin D2/56.7-g serving) and water (delivering 32,750 IU/250 mL) is similar and whether absorption differs between younger and older adults.",Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956292/),,32,160554,DB00169,Cholecalciferol
,16278401,C(max),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),[ng] / [ml],6.21,163154,DB00169,Cholecalciferol
,16278401,AUC(0-24),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),[h·ng] / [ml],41.3,163155,DB00169,Cholecalciferol
,16278401,AUC(0-infinity),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),,55.4,163156,DB00169,Cholecalciferol
,16278401,half-life (T(1/2)),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),h,16.2,163157,DB00169,Cholecalciferol
,2991323,MCR,"In the 13 normal subjects, the MCR values were within a narrow range, with a mean +/- SD value of 37 +/- 6 ml/min, which, when combined with the mean steady state concentration of endogenous 1,25-(OH)2D (42 +/- 6 pg/ml), yielded a mean production rate of 2.2 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[ml] / [min],37,167504,DB00169,Cholecalciferol
,2991323,steady state concentration,"In the 13 normal subjects, the MCR values were within a narrow range, with a mean +/- SD value of 37 +/- 6 ml/min, which, when combined with the mean steady state concentration of endogenous 1,25-(OH)2D (42 +/- 6 pg/ml), yielded a mean production rate of 2.2 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[pg] / [ml],42,167505,DB00169,Cholecalciferol
,2991323,production rate,"In the 13 normal subjects, the MCR values were within a narrow range, with a mean +/- SD value of 37 +/- 6 ml/min, which, when combined with the mean steady state concentration of endogenous 1,25-(OH)2D (42 +/- 6 pg/ml), yielded a mean production rate of 2.2 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[μg] / [d],2.2,167506,DB00169,Cholecalciferol
,2991323,MCR,"In the 9 patients with absorptive hypercalciuria, MCR values also were tightly clustered, with a mean of 35 +/- 4 ml/min.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[ml] / [min],35,167507,DB00169,Cholecalciferol
,2991323,production rate,"However, the mean endogenous steady state 1,25-(OH)2D level was significantly elevated in these patients, such that the calculated mean 1,25-(OH)2D production rate was significantly elevated at 3.4 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[μg] / [d],3.4,167508,DB00169,Cholecalciferol
,8076440,ka,"After i.v. administration A, ka, B, ke, t1/2, AUC24 and AUC0-->infinity were (mean +/- SD) 62.9 +/- 16.4 pg/ml, 0.76 +/- 0.30 h-1, 71.6 +/- 14.7 pg/ml, 0.017 +/- 0.015 h-1, 109.4 +/- 129.5 h, 1315.8 +/- 236.9 pg/ml x h and 10322.2 +/- 11473.7 pg/ml x h, respectively.","Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8076440/),[pg] / [ml],62.9,169579,DB00169,Cholecalciferol
,8076440,AUC0-->infinity,"After i.v. administration A, ka, B, ke, t1/2, AUC24 and AUC0-->infinity were (mean +/- SD) 62.9 +/- 16.4 pg/ml, 0.76 +/- 0.30 h-1, 71.6 +/- 14.7 pg/ml, 0.017 +/- 0.015 h-1, 109.4 +/- 129.5 h, 1315.8 +/- 236.9 pg/ml x h and 10322.2 +/- 11473.7 pg/ml x h, respectively.","Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8076440/),[pg] / [h·ml],10322.2,169580,DB00169,Cholecalciferol
,2004595,rate,"Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6-7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min).",On the mechanisms for the selective action of vitamin D analogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),[ml] / [min],48.2,170453,DB00169,Cholecalciferol
,2004595,rate,"Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6-7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min).",On the mechanisms for the selective action of vitamin D analogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),[ml] / [min],6.8,170454,DB00169,Cholecalciferol
,2004595,half-life,"The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3.",On the mechanisms for the selective action of vitamin D analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),h,2.5,170455,DB00169,Cholecalciferol
,2004595,half-life,"The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3.",On the mechanisms for the selective action of vitamin D analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),,7.0,170456,DB00169,Cholecalciferol
,2004595,MCR,Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4).,On the mechanisms for the selective action of vitamin D analogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),,56.8,170457,DB00169,Cholecalciferol
,2004595,t1/2,Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4).,On the mechanisms for the selective action of vitamin D analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),,2.1,170458,DB00169,Cholecalciferol
,12358640,terminal half-lives,"Calcitriol and paricalcitol have similar pharmacokinetic profiles, with terminal half-lives ranging from 5 to 10 hours in healthy subjects to 15-30 hours in patients undergoing dialysis.",Comparative review of the pharmacokinetics of vitamin D analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,5 to 10,175037,DB00169,Cholecalciferol
,12358640,terminal half-lives,"Calcitriol and paricalcitol have similar pharmacokinetic profiles, with terminal half-lives ranging from 5 to 10 hours in healthy subjects to 15-30 hours in patients undergoing dialysis.",Comparative review of the pharmacokinetics of vitamin D analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,15-30,175038,DB00169,Cholecalciferol
,12358640,half-life,"The half-life of 1alpha,25-(OH)2D2 is about 34 hours in healthy subjects and about 45 hours in dialysis patients, resembling physiologic blood concentrations of endogenous vitamin D.",Comparative review of the pharmacokinetics of vitamin D analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,34,175039,DB00169,Cholecalciferol
,12358640,half-life,"The half-life of 1alpha,25-(OH)2D2 is about 34 hours in healthy subjects and about 45 hours in dialysis patients, resembling physiologic blood concentrations of endogenous vitamin D.",Comparative review of the pharmacokinetics of vitamin D analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,45,175040,DB00169,Cholecalciferol
,222820,half-life,"Peak 25-hydroxycholecalciferol occurred at .6 wk, and half-life was 3.1 wk.",Pharmacokinetics and amounts of 25-hydroxycholecalciferol in sheep affected by osteodystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/222820/),wk,3.1,176333,DB00169,Cholecalciferol
,15379909,Peak concentrations,Peak concentrations of cholecalciferol were over twice those of ergocalciferol (570 +/- 80 vs. 264 +/- 42 nmol/l).,Cats discriminate between cholecalciferol and ergocalciferol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379909/),[nM] / [l],570,177948,DB00169,Cholecalciferol
,15379909,Peak concentrations,Peak concentrations of cholecalciferol were over twice those of ergocalciferol (570 +/- 80 vs. 264 +/- 42 nmol/l).,Cats discriminate between cholecalciferol and ergocalciferol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379909/),[nM] / [l],264,177949,DB00169,Cholecalciferol
,15531486,Area under the curve (AUC),Area under the curve (AUC) to d 28 was 60.2 ng.d/ml (150.5 nmol.d/liter) for vitamin D(2) and 204.7 (511.8) for vitamin D(3) (P < 0.002).,Vitamin D2 is much less effective than vitamin D3 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531486/),[d·ng] / [ml],60.2,183906,DB00169,Cholecalciferol
,15531486,Area under the curve (AUC),Area under the curve (AUC) to d 28 was 60.2 ng.d/ml (150.5 nmol.d/liter) for vitamin D(2) and 204.7 (511.8) for vitamin D(3) (P < 0.002).,Vitamin D2 is much less effective than vitamin D3 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531486/),[d·nM] / [l],150.5,183907,DB00169,Cholecalciferol
,15531486,Area under the curve (AUC),Area under the curve (AUC) to d 28 was 60.2 ng.d/ml (150.5 nmol.d/liter) for vitamin D(2) and 204.7 (511.8) for vitamin D(3) (P < 0.002).,Vitamin D2 is much less effective than vitamin D3 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531486/),,204.7,183908,DB00169,Cholecalciferol
,34008842,AUC,The PKS of 900 µg vitamin D3 revealed that malabsorptive patients had 64% lower AUC than healthy participants (1177 ± 425 vs. 3258 ± 496 ng · h/mL; P < 0.05).,"A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],1177,188321,DB00169,Cholecalciferol
,34008842,AUC,The PKS of 900 µg vitamin D3 revealed that malabsorptive patients had 64% lower AUC than healthy participants (1177 ± 425 vs. 3258 ± 496 ng · h/mL; P < 0.05).,"A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],3258,188322,DB00169,Cholecalciferol
,34008842,AUC,"The PKS of 900 µg vitamin D3 showed that the higher BMI group had 53% lower AUC than the lower BMI group (2089 ± 490 vs. 4427 ± 313 ng · h/mL; P < 0.05), whereas AUCs of 900 µg 25(OH)D3 were not significantly different between the 2 groups (P = 0.500).","A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],2089,188323,DB00169,Cholecalciferol
,34008842,AUC,"The PKS of 900 µg vitamin D3 showed that the higher BMI group had 53% lower AUC than the lower BMI group (2089 ± 490 vs. 4427 ± 313 ng · h/mL; P < 0.05), whereas AUCs of 900 µg 25(OH)D3 were not significantly different between the 2 groups (P = 0.500).","A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],4427,188324,DB00169,Cholecalciferol
,177440,t 1/2,"When analyzed several days after single 10 mug/kg oral doses of 25-hydroxycholecalciferol to 4 volunteers, the mean rate of decline to total serum 25-hydroxycholecalciferol was slow (t 1/2 = 22 days).",Acute administration of 25-hydroxycholecalciferol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/177440/),d,22,189135,DB00169,Cholecalciferol
,177440,apparent serum half-life,"When baseline serum 25-hydroxyvitamin D levels were subtracted, however, the apparent serum half-life of administered 25-hydroxycholecalciferol was 12 days, similar to that reported after tracer doses of 3H-25-hydroxycholecalciferol.",Acute administration of 25-hydroxycholecalciferol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/177440/),d,12,189136,DB00169,Cholecalciferol
,9510866,Enteral absorption,"Enteral absorption of the ion (9.77 +/- 0.438 mmol.L-1.min, 240 min after Sr administration), expressed as the area under the plasma concentration-time curve (AUC), and renal clearance (CRE) in these subjects during the test (2.80 +/- 0.336 mL/min) were not different from values for 27 controls.",Strontium absorption and excretion in normocalciuric subjects: relation to calcium metabolism. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510866/),[mM·min] / [l],9.77,190120,DB00169,Cholecalciferol
,9510866,renal clearance (CRE),"Enteral absorption of the ion (9.77 +/- 0.438 mmol.L-1.min, 240 min after Sr administration), expressed as the area under the plasma concentration-time curve (AUC), and renal clearance (CRE) in these subjects during the test (2.80 +/- 0.336 mL/min) were not different from values for 27 controls.",Strontium absorption and excretion in normocalciuric subjects: relation to calcium metabolism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510866/),[ml] / [min],2.80,190121,DB00169,Cholecalciferol
,6753604,half-life,"24,25-Dihydroxyvitamin D3 is rapidly cleared from the plasma with a half-life of approximately 390 +/- 25 min (mean +/- SE).","Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6753604/),min,390,197496,DB00169,Cholecalciferol
,6753604,metabolic clearance rate,"The metabolic clearance rate of 24,25-dihydroxyvitamin D3 was 9.2 +/- 1.5 liters/day with a production rate of 26.4 +/- 7.2 micrograms/day (mean +/- SE).","Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6753604/),[l] / [d],9.2,197497,DB00169,Cholecalciferol
,6753604,production rate,"The metabolic clearance rate of 24,25-dihydroxyvitamin D3 was 9.2 +/- 1.5 liters/day with a production rate of 26.4 +/- 7.2 micrograms/day (mean +/- SE).","Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6753604/),[μg] / [d],26.4,197498,DB00169,Cholecalciferol
,7478149,plasma half-life,"In summary, the biological effects of 1,25(OH)2D3 on the parathyroid glands probably persist for several days, although the plasma half-life of 1,25(OH)2D3 is only several hours.",Optimum mode of administration of vitamin D in renal failure. Insights from experimental data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7478149/),h,several,197690,DB00169,Cholecalciferol
,8954522,overall recovery,Mean overall recovery ranged from 71 to 89%.,An electron-capture dienophile derivatization agent for increasing sensitivity: determination of a vitamin D analog (Ro 24-2090) in plasma samples with liquid chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8954522/),%,71 to 89,197698,DB00169,Cholecalciferol
,6548386,t1/2,"Plasma pharmacokinetic studies in rats showed that (23S)-1,23,25-trihydroxy[3H]vitamin D3 was rapidly cleared from plasma (t1/2 = 60 min).","(23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1 alpha,25-dihydroxyvitamin D3 26,23-lactone biosynthesis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548386/),min,60,198092,DB00169,Cholecalciferol
,18318784,steady state oral clearance,"Cinacalcet steady state oral clearance was 131.1 +/- 20.9 l/h and 92.8 +/- 9.5 l/h (mean +/- SE) after 30 and 60 mg, respectively.",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),[l] / [h],131.1,205447,DB00169,Cholecalciferol
,18318784,steady state oral clearance,"Cinacalcet steady state oral clearance was 131.1 +/- 20.9 l/h and 92.8 +/- 9.5 l/h (mean +/- SE) after 30 and 60 mg, respectively.",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),[l] / [h],92.8,205448,DB00169,Cholecalciferol
,18318784,EC(50),"Cinacalcet and parathyroid hormone (PTH) concentrations showed an inverse correlation and were fitted to a simple E(max) model (E(max) = 80% reduction vs. baseline, EC(50) = 13 ng/mL).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),[ng] / [ml],13,205449,DB00169,Cholecalciferol
,18318784,fractional urinary excretion,"The 8-h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/- 0.17%, 30 mg 1.53 +/- 0.35%, 60 mg 1.92 +/- 0.37%).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),%,0.85,205450,DB00169,Cholecalciferol
,18318784,fractional urinary excretion,"The 8-h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/- 0.17%, 30 mg 1.53 +/- 0.35%, 60 mg 1.92 +/- 0.37%).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),%,1.53,205451,DB00169,Cholecalciferol
,18318784,fractional urinary excretion,"The 8-h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/- 0.17%, 30 mg 1.53 +/- 0.35%, 60 mg 1.92 +/- 0.37%).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),%,1.92,205452,DB00169,Cholecalciferol
,25098404,total chromatographic run time,The total chromatographic run time was 6.0 min and the elution of PAR and PAR-d6 occurred at ~2.6 min.,Sensitive method for the determination of paricalcitol by liquid chromatography and mass spectrometry and its application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25098404/),min,6.0,211872,DB00169,Cholecalciferol
,32471106,Total cumulative doses,"Total cumulative doses were: 588,000 IU, 600,000 IU, 600,000 IU.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),,"588,000",213481,DB00169,Cholecalciferol
,32471106,Total cumulative doses,"Total cumulative doses were: 588,000 IU, 600,000 IU, 600,000 IU.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),,600,213482,DB00169,Cholecalciferol
,32471106,peak values,"mean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),[ng] / [ml],81.0,213483,DB00169,Cholecalciferol
,32471106,peak values,"mean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),[ng] / [ml],63.6,213484,DB00169,Cholecalciferol
,32471106,peak values,"mean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),[ng] / [ml],59.4,213485,DB00169,Cholecalciferol
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],4.41,216425,DB00169,Cholecalciferol
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],5.17,216426,DB00169,Cholecalciferol
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],5.83,216427,DB00169,Cholecalciferol
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],6.06,216428,DB00169,Cholecalciferol
,16362456,calcium excretion,The increase in calcium excretion during the milk regimen was significant only for the old group: 0.96 vs. 0.28 mmol/day.,"Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],0.96,216429,DB00169,Cholecalciferol
,16362456,calcium excretion,The increase in calcium excretion during the milk regimen was significant only for the old group: 0.96 vs. 0.28 mmol/day.,"Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],0.28,216430,DB00169,Cholecalciferol
,2831435,plasma half-life,10-Keto-D3 exhibited a plasma half-life of only 6 min.,The biological assessment of vitamin D3 metabolites produced by rumen bacteria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2831435/),min,6,216942,DB00169,Cholecalciferol
>,21792336,IC(50),"The product showed minimal inhibition of 1A2, 2C19, 2D6, and 3A4, exhibiting IC(50) > 10 μM, but 2C8 and 2C9 yielded IC(50) of 2.5 μM and 2.8 μM, respectively, concentrations which are theroretically achievable when dosing the product twice daily.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),μM,10,221623,DB00169,Cholecalciferol
,21792336,IC(50),"The product showed minimal inhibition of 1A2, 2C19, 2D6, and 3A4, exhibiting IC(50) > 10 μM, but 2C8 and 2C9 yielded IC(50) of 2.5 μM and 2.8 μM, respectively, concentrations which are theroretically achievable when dosing the product twice daily.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),μM,2.5,221624,DB00169,Cholecalciferol
,21792336,IC(50),"The product showed minimal inhibition of 1A2, 2C19, 2D6, and 3A4, exhibiting IC(50) > 10 μM, but 2C8 and 2C9 yielded IC(50) of 2.5 μM and 2.8 μM, respectively, concentrations which are theroretically achievable when dosing the product twice daily.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),μM,2.8,221625,DB00169,Cholecalciferol
,21792336,time to peak concentration,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),h,1.88,221626,DB00169,Cholecalciferol
,21792336,maximum concentration reached,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),μM,0.052,221627,DB00169,Cholecalciferol
,21792336,elimination half-life,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),h,2.3,221628,DB00169,Cholecalciferol
,21792336,area under the concentration-time curve,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),[h·ng] / [ml],53.75,221629,DB00169,Cholecalciferol
,21792336,time to peak concentration,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),h,2.22,221630,DB00169,Cholecalciferol
,21792336,maximum concentration reached,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),μM,2.95,221631,DB00169,Cholecalciferol
,21792336,elimination half-life,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),h,10.4,221632,DB00169,Cholecalciferol
,21792336,area under the concentration-time curve,"After seven days of administration in a steady-state pharmacokinetic study, significant differences were found for unconjugated genistein (including free and protein-bound), regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached (0.052 ± 0.055 μM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-time curve (53.75 ± 17.59 ng · hour/mL) compared with results for total genistein (including glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), maximum concentration reached (2.95 ± 1.64 μM), elimination half-life (10.4 ± 4.1 hours), and area under the concentration-time curve (10424 ± 6290 ng · hour/mL) in fasting subjects.",Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21792336/),[h·ng] / [ml],10424,221633,DB00169,Cholecalciferol
,19396601,peak serum calcitriol concentration (C (max)),Mean (+/-SE) peak serum calcitriol concentration (C (max)) at the MTD (125 microg/week calcitriol) was 11.17 +/- 2.62 ng/ml and the systemic exposure (AUC(0-72 h)) of 53.30 +/- 10.49 ng h/ml.,A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396601/),[ng] / [ml],11.17,222257,DB00169,Cholecalciferol
,19396601,AUC(0-72 h)),Mean (+/-SE) peak serum calcitriol concentration (C (max)) at the MTD (125 microg/week calcitriol) was 11.17 +/- 2.62 ng/ml and the systemic exposure (AUC(0-72 h)) of 53.30 +/- 10.49 ng h/ml.,A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396601/),[h·ng] / [ml],53.30,222258,DB00169,Cholecalciferol
,9623560,time: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),weeks,14.2,225118,DB00169,Cholecalciferol
,9623560,time: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),weeks,12.2,225119,DB00169,Cholecalciferol
,9623560,rate: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),[%·pth] / [week],7.4,225120,DB00169,Cholecalciferol
,9623560,rate: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),[%·pth] / [week],8.4,225121,DB00169,Cholecalciferol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,33,225556,DB00169,Cholecalciferol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,19,225557,DB00169,Cholecalciferol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,73,225558,DB00169,Cholecalciferol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,43,225559,DB00169,Cholecalciferol
,17066293,MTD,The MTD for weekly DN-101 was established as 45 mug.,"Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17066293/),μg,45,232515,DB00169,Cholecalciferol
,23268736,peak rise,"Mean peak rise in serum 25-hydroxyvitamin D concentration above baseline was similar in non-pregnant and pregnant women (28 nmol/L and 32 nmol/L, respectively).","Pharmacokinetics of a single oral dose of vitamin D3 (70,000 IU) in pregnant and non-pregnant women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23268736/),,28,235339,DB00169,Cholecalciferol
,23268736,peak rise,"Mean peak rise in serum 25-hydroxyvitamin D concentration above baseline was similar in non-pregnant and pregnant women (28 nmol/L and 32 nmol/L, respectively).","Pharmacokinetics of a single oral dose of vitamin D3 (70,000 IU) in pregnant and non-pregnant women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23268736/),,32,235340,DB00169,Cholecalciferol
,1151140,half-lives,"Following intraperitoneal injection of equal (or 3-fold larger doses to older pups) doses of 'H-25-hydroxycholecalciferol, the half-lives of 'H in plasma were 2.9 to 3.0 days and 2.8 to 3.05 days in young and oldersuckling pups, respectively.",Postnatal fall and rise of circulating 25-hydroxyvitamin D in the rat*. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1151140/),d,2.9 to 3.0,236932,DB00169,Cholecalciferol
,1151140,half-lives,"Following intraperitoneal injection of equal (or 3-fold larger doses to older pups) doses of 'H-25-hydroxycholecalciferol, the half-lives of 'H in plasma were 2.9 to 3.0 days and 2.8 to 3.05 days in young and oldersuckling pups, respectively.",Postnatal fall and rise of circulating 25-hydroxyvitamin D in the rat*. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1151140/),d,2.8 to 3.05,236933,DB00169,Cholecalciferol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,84,239510,DB00169,Cholecalciferol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,111,239511,DB00169,Cholecalciferol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,33,239512,DB00169,Cholecalciferol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,82,239513,DB00169,Cholecalciferol
,27569392,Tmax,The intervention markedly increased the blood 25(OH)D3 levels within the first five days (mean Tmax=5.1±2.1 d) and sustained an optimal circulating level of 25(OH)D3 (≥30 ng/mL) for 56 d.,Pharmacokinetics and effects of demographic factors on blood 25(OH)D3 levels after a single orally administered high dose of vitamin D3. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569392/),d,5.1,240846,DB00169,Cholecalciferol
,2347542,MCR,The MCR averaged 0.201 +/- 0.003 ml.min-1.kg-1 in fed male rats weighing 200-300 g.,"Production and metabolic clearance rates of 1,25-dihydroxyvitamin D3 during maturation in rats: studies using a rapid, primed-infusion technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2347542/),[ml] / [kg·min],0.201,249811,DB00169,Cholecalciferol
,24440824,limit of detection,The method was validated over the linear range of 1.0-5000ng/ml (r(2)=0.999) for both vitamins with a limit of detection of 0.5ng/ml.,Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),[ng] / [ml],0.5,254735,DB00169,Cholecalciferol
,24440824,flow rate,"Chromatographic separation was achieved using liquid-liquid extraction (LLE) on an Acquity BEH RP 18 column (2.1mm×50mm, I.D. 1.7μm), with mobile phase comprising of acetonitrile:methanol:water (90:8:2, v/v/v), at a flow rate of 0.20ml/min and a total run time of 5min.",Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),[ml] / [min],0.20,254736,DB00169,Cholecalciferol
,24440824,total run time,"Chromatographic separation was achieved using liquid-liquid extraction (LLE) on an Acquity BEH RP 18 column (2.1mm×50mm, I.D. 1.7μm), with mobile phase comprising of acetonitrile:methanol:water (90:8:2, v/v/v), at a flow rate of 0.20ml/min and a total run time of 5min.",Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),min,5,254737,DB00169,Cholecalciferol
≥,24440824,recovery,High recovery of ≥96.0% for ATRA and ≥87.80% for vitamin D3 was achieved.,Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),%,96.0,254738,DB00169,Cholecalciferol
≥,24440824,recovery,High recovery of ≥96.0% for ATRA and ≥87.80% for vitamin D3 was achieved.,Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),%,87.80,254739,DB00169,Cholecalciferol
,3753709,PR,"With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38 +/- 3 to 68 +/- 6 pg/ml, P less than 0.001; the PR increased from 1.8 +/- 0.2 to 3.8 +/- 0.6 micrograms/d, P less than 0.005; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,1,260591,DB00169,Cholecalciferol
,3753709,PR,"With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38 +/- 3 to 68 +/- 6 pg/ml, P less than 0.001; the PR increased from 1.8 +/- 0.2 to 3.8 +/- 0.6 micrograms/d, P less than 0.005; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,3,260592,DB00169,Cholecalciferol
,3753709,PR,"The PR decreased to 1.3 +/- 0.2 micrograms/d, P less than 0.05; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,1,260593,DB00169,Cholecalciferol
,21732345,MTD,"Remarkably, dose challenge experiments revealed that inecalcitol maximal tolerated dose (MTD) by intraperitoneal (i.p.) administration was 30 μg/mouse (1,300 μg/kg) three times per week, while we previously found that the MTD of 1,25(OH)(2) D(3) is 0.0625 μg/mouse; therefore, inecalcitol is 480 times less hypercalcemic than 1,25(OH)(2) D(3) .","Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21732345/),[μg] / [mouse],0.0625,264904,DB00169,Cholecalciferol
,21732345,plasma half-life,Pharmacokinetic studies showed that plasma half-life of inecalcitol were 18.3 min in mice.,"Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21732345/),min,18.3,264905,DB00169,Cholecalciferol
,31067745,area under the concentration curve (AUC),"In Study 2, the area under the concentration curve (AUC) was higher with gummies than tablets (gummy mean (95% CI): 1474 ng·/mL (1393-1555); tablet mean (95% CI): 774 ng·h/mL (693-855), p < 0.0001).",Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067745/),[ng] / [ml],1474,269631,DB00169,Cholecalciferol
,31067745,area under the concentration curve (AUC),"In Study 2, the area under the concentration curve (AUC) was higher with gummies than tablets (gummy mean (95% CI): 1474 ng·/mL (1393-1555); tablet mean (95% CI): 774 ng·h/mL (693-855), p < 0.0001).",Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067745/),[h·ng] / [ml],774,269632,DB00169,Cholecalciferol
,31067745,peak blood concentration (Cmax),Average peak blood concentration (Cmax) values were significantly higher with gummies (gummy: 47.3 ng/mL; tablet: 23.4 ng/mL; p < 0.0001).,Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067745/),[ng] / [ml],47.3,269633,DB00169,Cholecalciferol
,31067745,peak blood concentration (Cmax),Average peak blood concentration (Cmax) values were significantly higher with gummies (gummy: 47.3 ng/mL; tablet: 23.4 ng/mL; p < 0.0001).,Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067745/),[ng] / [ml],23.4,269634,DB00169,Cholecalciferol
,3623424,FACa,"In the basal state, the radiocalcium transit was significantly decreased (P less than 0.02) at 15 min in patients treated with prednisolone, but FACa at 6 h was not significantly decreased (51 +/- 5 vs. 60 +/- 5% TD).",Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623424/),%,51,272503,DB00169,Cholecalciferol
,3623424,FACa,"In the basal state, the radiocalcium transit was significantly decreased (P less than 0.02) at 15 min in patients treated with prednisolone, but FACa at 6 h was not significantly decreased (51 +/- 5 vs. 60 +/- 5% TD).",Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623424/),%,60,272504,DB00169,Cholecalciferol
